New combo could help more liver cancer patients get transplants
NCT ID NCT07059494
First seen Nov 05, 2025 · Last updated Apr 28, 2026 · Updated 30 times
Summary
This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough for patients to qualify for a liver transplant. It includes 40 adults with liver cancer who either need to shrink tumors to meet transplant criteria or have high AFP levels. The goal is to see how many patients respond well enough within 9 months to proceed with transplantation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Conditions
Explore the condition pages connected to this study.